Study S001287

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03730662
Acronym: SURPASS-4
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 2002
Start: 2018-11-20
Primary completion: 2021-01-22
Lead sponsor: Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Tirzepatide; DRUG:Insulin Glargine
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPGM; EUDRACT_NUMBER:2018-002618-11; NIH:2018

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) [Baseline, Week 52]

Linked records (8)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010804	Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics. De Block C, Diabetes therapy : research, treatment and education of diabetes and related disorders	2025	Randomized trial	PMID 39531161 DOI	cites ClinicalTrials.gov:NCT03730662; registry reference DERIVED:39531161
R0015279	Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4. Guan H, Diabetes, obesity & metabolism	2025	Randomized trial	PMID 40926359 DOI	cites ClinicalTrials.gov:NCT03730662
R0007531	Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme. Boye KS, Diabetes therapy : research, treatment and education of diabetes and related disorders	2023	Other trial	PMID 37526908 DOI	cites ClinicalTrials.gov:NCT03730662; registry reference DERIVED:37526908
R0009342	Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide. Boye KS, Diabetes therapy : research, treatment and education of diabetes and related disorders	2023	Other trial	PMID 37668888 DOI	cites ClinicalTrials.gov:NCT03730662; registry reference DERIVED:37668888
R0012252	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Sattar N, Nature medicine	2022	Systematic review	PMID 35210595 DOI	cites ClinicalTrials.gov:NCT03730662; registry reference DERIVED:35210595
R0018699	Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Heerspink HJL, The lancet. Diabetes & endocrinology	2022	Randomized trial	PMID 36152639 DOI	cites ClinicalTrials.gov:NCT03730662; registry reference DERIVED:36152639
R0023137	Tirzepatide-Friend or Foe in Diabetic Cancer Patients? Samuel SM, Biomolecules	2022	Other trial	PMID 36358930 DOI	cites ClinicalTrials.gov:NCT03730662
R0019366	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Del Prato S, Lancet (London, England)	2021	Randomized trial	PMID 34672967 DOI	cites ClinicalTrials.gov:NCT03730662; registry reference DERIVED:34672967